Overall Response Rate and solid tumors – the magic number… to date
With the rise of immunotherapies for cancer, the limitations of RECIST-based evaluation are becoming more important.
This content is intended for healthcare professionals based in the United States. Please confirm you are a US healthcare professional:
CM-UK--2500026
DOP: August 2025